 |
|
Non-invasive tests-based risk stratification: Baveno VII and beyond
Georg Semmler, Mathias Jachs, Mattias Mandorfer
Clin Mol Hepatol. 2023;29(1):105-109. Published online 2022 Nov 23 DOI: https://doi.org/10.3350/cmh.2022.0361
|
|
Citations to this article as recorded by
 Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension
Georg Semmler, Lukas Hartl, Yuly Paulin Mendoza, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Michael Schwarz, Benedikt Silvester Hofer, Laurenz Fritz, Anna Schedlbauer, Katharina Stopfer, Daniela Neumayer, Jurij Maurer, Robin Szymanski, Elias Lauri
Hepatology.2024;[Epub] CrossRef Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
Clinical and Molecular Hepatology.2023; 29(1): 188. CrossRef Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII
Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn
Liver International.2023; 43(9): 1966. CrossRef Lymphatic drainage dysfunction is related to clinically significant portal hypertension
Ruixue Ma, Yasuko Iwakiri
Hepatology International.2023; 17(6): 1327. CrossRef
|